Format
Sort by
Items per page

Send to

Choose Destination

Search results

Items: 1 to 50 of 66

1.

Allogeneic hematopoietic cell transplantation compared to chemotherapy consolidation in older acute myeloid leukemia (AML) patients 60-75 years in first complete remission (CR1): an alliance (A151509), SWOG, ECOG-ACRIN, and CIBMTR study.

Ustun C, Le-Rademacher J, Wang HL, Othus M, Sun Z, Major B, Zhang MJ, Storrick E, Lafky JM, Chow S, Mrózek K, Attar EC, Nand S, Bloomfield CD, Cripe LD, Tallman MS, Appelbaum F, Larson RA, Marcucci G, Roboz GJ, Uy GL, Stone RM, Jatoi A, Shea TC, de Lima M, Foran JM, Sandmaier BM, Litzow MR, Erba HP, Hurria A, Weisdorf DJ, Artz AS.

Leukemia. 2019 May 9. doi: 10.1038/s41375-019-0477-x. [Epub ahead of print]

PMID:
31073153
2.

Combination of sorafenib, vorinostat and bortezomib for the treatment of poor-risk AML: report of two consecutive clinical trials.

Sayar H, Cripe LD, Saliba AN, Abu Zaid M, Konig H, Boswell HS.

Leuk Res. 2019 Feb;77:30-33. doi: 10.1016/j.leukres.2018.12.011. Epub 2018 Dec 24. No abstract available.

PMID:
30626561
3.

Evidence of a role for functional heterogeneity in multidrug resistance transporters in clinical trials of P-glycoprotein modulation in acute myeloid leukemia.

Marcelletti JF, Sikic BI, Cripe LD, Paietta E.

Cytometry B Clin Cytom. 2019 Jan;96(1):57-66. doi: 10.1002/cyto.b.21737. Epub 2018 Oct 17.

PMID:
30334334
4.

Ambulatory Advanced Cancer Patients' and Oncologists' Estimates of Life Expectancy Are Associated with Patient Psychological Characteristics But Not Chemotherapy Use.

Cripe LD, Rand KL, Perkins SM, Tong Y, Schmidt KK, Hedrick DG, Rawl SM.

J Palliat Med. 2018 Aug;21(8):1107-1113. doi: 10.1089/jpm.2017.0686. Epub 2018 Jun 15.

PMID:
29905496
5.

Very poor long-term survival in past and more recent studies for relapsed AML patients: The ECOG-ACRIN experience.

Ganzel C, Sun Z, Cripe LD, Fernandez HF, Douer D, Rowe JM, Paietta EM, Ketterling R, O'Connell MJ, Wiernik PH, Bennett JM, Litzow MR, Luger SM, Lazarus HM, Tallman MS.

Am J Hematol. 2018 Jun 15. doi: 10.1002/ajh.25162. [Epub ahead of print]

6.

Predicting symptoms of anxiety and depression in patients living with advanced cancer: the differential roles of hope and optimism.

Fischer IC, Cripe LD, Rand KL.

Support Care Cancer. 2018 Oct;26(10):3471-3477. doi: 10.1007/s00520-018-4215-0. Epub 2018 Apr 21.

PMID:
29681016
7.

Differences between Supportive Music and Imagery and Music Listening during Outpatient Chemotherapy and Potential Moderators of Treatment Effects.

Burns DS, Meadows AN, Althouse S, Perkins SM, Cripe LD.

J Music Ther. 2018 Mar 9;55(1):83-108. doi: 10.1093/jmt/thy001. Erratum in: J Music Ther. 2018 Jun 7;55(2):254.

PMID:
29471518
8.

Consecutive epigenetically-active agent combinations act in ID1-RUNX3-TET2 and HOXA pathways for Flt3ITD+ve AML.

Sayar H, Liu Y, Gao R, Zaid MA, Cripe LD, Weisenbach J, Sargent KJ, Nassiri M, Li L, Konig H, Suvannasankha A, Pan F, Shanmugam R, Goswami C, Kapur R, Xu M, Boswell HS.

Oncotarget. 2017 Dec 25;9(5):5703-5715. doi: 10.18632/oncotarget.23655. eCollection 2018 Jan 19.

9.

"My Future is Now": A Qualitative Study of Persons Living With Advanced Cancer.

Cottingham AH, Cripe LD, Rand KL, Frankel RM.

Am J Hosp Palliat Care. 2018 Apr;35(4):640-646. doi: 10.1177/1049909117734826. Epub 2017 Oct 9.

PMID:
28992715
10.

Dying From Cancer: Communication, Empathy, and the Clinical Imagination.

Cripe LD, Frankel RM.

J Patient Exp. 2017 Jun;4(2):69-73. doi: 10.1177/2374373517699443. Epub 2017 May 11.

11.

Independent Prognostic Significance of Monosomy 17 and Impact of Karyotype Complexity in Monosomal Karyotype/Complex Karyotype Acute Myeloid Leukemia: Results from Four ECOG-ACRIN Prospective Therapeutic Trials.

Strickland SA, Sun Z, Ketterling RP, Cherry AM, Cripe LD, Dewald G, Fernandez HF, Hicks GA, Higgins RR, Lazarus HM, Litzow MR, Luger SM, Paietta EM, Rowe JM, Vance GH, Wiernik P, Wiktor AE, Zhang Y, Tallman MS; ECOG-ACRIN Cancer Research Group.

Leuk Res. 2017 Aug;59:55-64. doi: 10.1016/j.leukres.2017.05.010. Epub 2017 May 12.

12.

Extramedullary Disease in Adult Acute Myeloid Leukemia Is Common but Lacks Independent Significance: Analysis of Patients in ECOG-ACRIN Cancer Research Group Trials, 1980-2008.

Ganzel C, Manola J, Douer D, Rowe JM, Fernandez HF, Paietta EM, Litzow MR, Lee JW, Luger SM, Lazarus HM, Cripe LD, Wiernik PH, Tallman MS.

J Clin Oncol. 2016 Oct 10;34(29):3544-3553. Erratum in: J Clin Oncol. 2017 Jan 10;35(2):263.

13.

Physicians in Postgraduate Training Characteristics and Support of Palliative Sedation for Existential Distress.

Cripe LD, Perkins SM, Cottingham A, Tong Y, Kozak MA, Mehta R.

Am J Hosp Palliat Care. 2017 Sep;34(8):697-703. doi: 10.1177/1049909116660516. Epub 2016 Jul 18.

14.

Life and treatment goals of patients with advanced, incurable cancer.

Rand KL, Banno DA, Shea AM, Cripe LD.

Support Care Cancer. 2016 Jul;24(7):2953-62. doi: 10.1007/s00520-016-3113-6. Epub 2016 Feb 11.

PMID:
26864986
15.

A PIECE OF MY MIND. Hope Is the Thing With Feathers.

Cripe LD.

JAMA. 2016 Jan 19;315(3):265-6. doi: 10.1001/jama.2015.18557. No abstract available.

PMID:
26784772
16.

Medical Students' Professionalism Narratives Reveal That Experiences With Death, Dying, or Palliative Care Are More Positive Than Other Experiences During Their Internal Medicine Clerkship.

Cripe LD, Hedrick DG, Rand KL, Burns D, Banno D, Cottingham A, Litzelman D, Hoffmann ML, Martenyi N, Frankel RM.

Am J Hosp Palliat Care. 2017 Feb;34(1):79-84. doi: 10.1177/1049909115609296. Epub 2016 Jul 11.

PMID:
26430135
17.

Cell signaling-based classifier predicts response to induction therapy in elderly patients with acute myeloid leukemia.

Cesano A, Willman CL, Kopecky KJ, Gayko U, Putta S, Louie B, Westfall M, Purvis N, Spellmeyer DC, Marimpietri C, Cohen AC, Hackett J, Shi J, Walker MG, Sun Z, Paietta E, Tallman MS, Cripe LD, Atwater S, Appelbaum FR, Radich JP.

PLoS One. 2015 Apr 17;10(4):e0118485. doi: 10.1371/journal.pone.0118485. eCollection 2015.

18.

Music Therapy is Associated With Family Perception of More Spiritual Support and Decreased Breathing Problems in Cancer Patients Receiving Hospice Care.

Burns DS, Perkins SM, Tong Y, Hilliard RE, Cripe LD.

J Pain Symptom Manage. 2015 Aug;50(2):225-31. doi: 10.1016/j.jpainsymman.2015.02.022. Epub 2015 Apr 1.

19.

Pilot study of erlotinib in patients with acute myeloid leukemia.

Sayar H, Czader M, Amin C, Cangany M, Konig H, Cripe LD.

Leuk Res. 2015 Feb;39(2):170-2. doi: 10.1016/j.leukres.2014.11.022. Epub 2014 Dec 2.

PMID:
25498508
20.

REVEAL-1, a phase 2 dose regimen optimization study of vosaroxin in older poor-risk patients with previously untreated acute myeloid leukaemia.

Stuart RK, Cripe LD, Maris MB, Cooper MA, Stone RM, Dakhil SR, Turturro F, Stock W, Mason J, Shami PJ, Strickland SA, Costa LJ, Borthakur G, Michelson GC, Fox JA, Leavitt RD, Ravandi F.

Br J Haematol. 2015 Mar;168(6):796-805. doi: 10.1111/bjh.13214. Epub 2014 Nov 17.

21.

A phase 1b/2 study of vosaroxin in combination with cytarabine in patients with relapsed or refractory acute myeloid leukemia.

Lancet JE, Roboz GJ, Cripe LD, Michelson GC, Fox JA, Leavitt RD, Chen T, Hawtin R, Craig AR, Ravandi F, Maris MB, Stuart RK, Karp JE.

Haematologica. 2015 Feb;100(2):231-7. doi: 10.3324/haematol.2014.114769. Epub 2014 Nov 7.

22.

Cyclophosphamide/fludarabine nonmyeloablative allotransplant for acute myeloid leukemia.

Khawaja MR, Perkins SM, Schwartz JE, Robertson MJ, Kiel PJ, Sayar H, Cox EA, Vance GH, Farag SS, Cripe LD, Nelson RP Jr.

Am J Hematol. 2015 Feb;90(2):97-9. doi: 10.1002/ajh.23875.

23.

Functional pathway analysis in acute myeloid leukemia using single cell network profiling assay: effect of specimen source (bone marrow or peripheral blood) on assay readouts.

Cesano A, Rosen DB, O'Meara P, Putta S, Gayko U, Spellmeyer DC, Cripe LD, Sun Z, Uno H, Litzow MR, Tallman MS, Paietta E.

Cytometry B Clin Cytom. 2012 May;82(3):158-72. doi: 10.1002/cyto.b.21007. Epub 2012 Feb 14.

24.

Cytarabine in relapsed acute myeloid leukemia.

Hardesty BM, Cripe LD.

Leuk Res. 2012 Apr;36(4):387-8. doi: 10.1016/j.leukres.2011.12.001. Epub 2012 Jan 28. No abstract available.

PMID:
22285506
25.

Discussions of life expectancy moderate relationships between prognosis and anxiety or depression in men with advanced cancer.

Cripe LD, Rawl SM, Schmidt KK, Tong Y, Monahan PO, Rand KL.

J Palliat Med. 2012 Jan;15(1):99-105. doi: 10.1089/jpm.2011.0249.

PMID:
22268405
26.

A noncanonical Flt3ITD/NF-κB signaling pathway represses DAPK1 in acute myeloid leukemia.

Shanmugam R, Gade P, Wilson-Weekes A, Sayar H, Suvannasankha A, Goswami C, Li L, Gupta S, Cardoso AA, Baghdadi TA, Sargent KJ, Cripe LD, Kalvakolanu DV, Boswell HS.

Clin Cancer Res. 2012 Jan 15;18(2):360-369. doi: 10.1158/1078-0432.CCR-10-3022. Epub 2011 Nov 17.

27.

Illness appraisal, religious coping, and psychological responses in men with advanced cancer.

Rand KL, Cripe LD, Monahan PO, Tong Y, Schmidt K, Rawl SM.

Support Care Cancer. 2012 Aug;20(8):1719-28. doi: 10.1007/s00520-011-1265-y. Epub 2011 Sep 18.

PMID:
21927993
28.

A phase Ib study of vosaroxin, an anticancer quinolone derivative, in patients with relapsed or refractory acute leukemia.

Lancet JE, Ravandi F, Ricklis RM, Cripe LD, Kantarjian HM, Giles FJ, List AF, Chen T, Allen RS, Fox JA, Michelson GC, Karp JE.

Leukemia. 2011 Dec;25(12):1808-14. doi: 10.1038/leu.2011.157. Epub 2011 Jul 15.

29.

Trustworthiness.

Cripe LD.

J Clin Oncol. 2011 Sep 1;29(25):3483-6. doi: 10.1200/JCO.2011.35.9463. Epub 2011 Jun 6. No abstract available.

PMID:
21646614
30.

Thrice weekly azacitidine does not improve hematological responses in lower-risk myelodysplastic syndromes: a study of the Hoosier Oncology Group.

Sayar H, Chan RJ, Orschell CM, Chan EM, Yu Z, Hood D, Plett A, Yang Z, Hui CL, Nabinger SC, Kohlbacher KJ, West ES, Walter A, Sampson C, Wu J, Cripe LD.

Leuk Res. 2011 Aug;35(8):1108-10. doi: 10.1016/j.leukres.2011.02.025. Epub 2011 Mar 21.

PMID:
21420732
31.

Results from a randomized trial of salvage chemotherapy followed by lestaurtinib for patients with FLT3 mutant AML in first relapse.

Levis M, Ravandi F, Wang ES, Baer MR, Perl A, Coutre S, Erba H, Stuart RK, Baccarani M, Cripe LD, Tallman MS, Meloni G, Godley LA, Langston AA, Amadori S, Lewis ID, Nagler A, Stone R, Yee K, Advani A, Douer D, Wiktor-Jedrzejczak W, Juliusson G, Litzow MR, Petersdorf S, Sanz M, Kantarjian HM, Sato T, Tremmel L, Bensen-Kennedy DM, Small D, Smith BD.

Blood. 2011 Mar 24;117(12):3294-301. doi: 10.1182/blood-2010-08-301796. Epub 2011 Jan 26.

32.

Zosuquidar, a novel modulator of P-glycoprotein, does not improve the outcome of older patients with newly diagnosed acute myeloid leukemia: a randomized, placebo-controlled trial of the Eastern Cooperative Oncology Group 3999.

Cripe LD, Uno H, Paietta EM, Litzow MR, Ketterling RP, Bennett JM, Rowe JM, Lazarus HM, Luger S, Tallman MS.

Blood. 2010 Nov 18;116(20):4077-85. doi: 10.1182/blood-2010-04-277269. Epub 2010 Aug 17.

33.

Lenalidomide and prednisone for myelofibrosis: Eastern Cooperative Oncology Group (ECOG) phase 2 trial E4903.

Mesa RA, Yao X, Cripe LD, Li CY, Litzow M, Paietta E, Rowe JM, Tefferi A, Tallman MS.

Blood. 2010 Nov 25;116(22):4436-8. doi: 10.1182/blood-2010-05-287417. Epub 2010 Jul 22.

34.

Long-term disease-free survival after nonmyeloablative cyclophosphamide/fludarabine conditioning and related/unrelated allotransplantation for acute myeloid leukemia/myelodysplasia.

Nelson RP Jr, Yu M, Schwartz JE, Robertson MJ, Hromas R, Fausel CA, Vance GH, Dlouhy SR, Baute JA, Cox EA, Wood LL, Srivastava S, Robertson KA, Haut PR, Farag SS, Abonour R, Cornetta K, Cripe LD.

Bone Marrow Transplant. 2010 Aug;45(8):1300-8. doi: 10.1038/bmt.2009.348. Epub 2010 Jan 11.

PMID:
20062092
35.

Inhibition of Syk with fostamatinib disodium has significant clinical activity in non-Hodgkin lymphoma and chronic lymphocytic leukemia.

Friedberg JW, Sharman J, Sweetenham J, Johnston PB, Vose JM, Lacasce A, Schaefer-Cutillo J, De Vos S, Sinha R, Leonard JP, Cripe LD, Gregory SA, Sterba MP, Lowe AM, Levy R, Shipp MA.

Blood. 2010 Apr 1;115(13):2578-85. doi: 10.1182/blood-2009-08-236471. Epub 2009 Nov 17.

36.

Failure of three novel regimens to improve outcome for patients with relapsed or refractory acute myeloid leukaemia: a report from the Eastern Cooperative Oncology Group.

Litzow MR, Othus M, Cripe LD, Gore SD, Lazarus HM, Lee SJ, Bennett JM, Paietta EM, Dewald GW, Rowe JM, Tallman MS; Eastern Cooperative Oncology Group Leukemia Committee.

Br J Haematol. 2010 Jan;148(2):217-25. doi: 10.1111/j.1365-2141.2009.07917.x. Epub 2009 Oct 5.

37.

Foreword. The discovered story: the evolution of truth in cancer narratives.

Cripe LD.

Lit Med. 2009 Fall;28(2):vi-x. No abstract available.

PMID:
21141791
38.

Dying pretty.

Cripe LD.

J Palliat Med. 2009 Sep;12(9):839-40. doi: 10.1089/jpm.2009.0104. No abstract available.

PMID:
19719376
39.

A piece of my mind. Giving up.

Cripe LD.

JAMA. 2009 May 6;301(17):1747-8. doi: 10.1001/jama.2009.550. No abstract available.

PMID:
19417181
40.

Treating low-risk myelodysplastic syndromes in the community setting.

Cripe LD.

Clin Adv Hematol Oncol. 2008 Jun;6(6):418-20. No abstract available.

PMID:
18567986
41.

Music imagery for adults with acute leukemia in protective environments: a feasibility study.

Burns DS, Azzouz F, Sledge R, Rutledge C, Hincher K, Monahan PO, Cripe LD.

Support Care Cancer. 2008 May;16(5):507-13. Epub 2007 Sep 22.

PMID:
17891547
42.

Final report of toxicity and efficacy of a phase II study of oral cyclophosphamide, thalidomide, and prednisone for patients with relapsed or refractory multiple myeloma: A Hoosier Oncology Group Trial, HEM01-21.

Suvannasankha A, Fausel C, Juliar BE, Yiannoutsos CT, Fisher WB, Ansari RH, Wood LL, Smith GG, Cripe LD, Abonour R.

Oncologist. 2007 Jan;12(1):99-106.

43.

A piece of my mind. Hope is the thing with feathers.

Cripe LD.

JAMA. 2006 Oct 18;296(15):1815-6. No abstract available.

PMID:
17047201
44.

Constitutive c-jun N-terminal kinase activity in acute myeloid leukemia derives from Flt3 and affects survival and proliferation.

Hartman AD, Wilson-Weekes A, Suvannasankha A, Burgess GS, Phillips CA, Hincher KJ, Cripe LD, Boswell HS.

Exp Hematol. 2006 Oct;34(10):1360-76.

PMID:
16982329
45.

Desensitization to imatinib in patients with leukemia.

Nelson RP Jr, Cornetta K, Ward KE, Ramanuja S, Fausel C, Cripe LD.

Ann Allergy Asthma Immunol. 2006 Aug;97(2):216-22.

PMID:
16937754
46.

Oncologist Assisted Spiritual Intervention Study (OASIS): patient acceptability and initial evidence of effects.

Kristeller JL, Rhodes M, Cripe LD, Sheets V.

Int J Psychiatry Med. 2005;35(4):329-47.

PMID:
16673834
47.

Phase II clinical studies of denileukin diftitox diphtheria toxin fusion protein in patients with previously treated chronic lymphocytic leukemia.

Frankel AE, Surendranathan A, Black JH, White A, Ganjoo K, Cripe LD.

Cancer. 2006 May 15;106(10):2158-64.

48.
49.

12-O-Tetradecanoylphorbol-13-acetate in acute myeloid leukemia.

Chan RJ, Cripe LD.

Leuk Res. 2005 Oct;29(10):1107-8. No abstract available.

PMID:
15913776
50.

A phase II study of single agent gemcitabine in relapsed or refractory follicular or small lymphocytic non-Hodgkin lymphomas: a Hoosier Oncology Group Study.

Ganjoo KN, Robertson MJ, Fisher W, Jung SH, McClean J, Huh SY, Bufill J, Williams S, Cripe LD.

Am J Clin Oncol. 2005 Apr;28(2):169-72.

PMID:
15803012

Supplemental Content

Loading ...
Support Center